Home
AVIR
AVIR News

Latest Atea Pharmaceuticals Inc. (AVIR) News on January 22, 2025

Argus Research

a day ago

Daily – Vickers Top Buyers & Sellers for 01/21/2025

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

9 days ago

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

14 days ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

US Penny Stocks To Watch In December 2024

Simply Wall St.

a month ago

US Penny Stocks To Watch In December 2024

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

GlobeNewswire

a month ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir

TipRanks

2 months ago

Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Benzinga

2 months ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

GlobeNewswire

2 months ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Atea plans Phase 3 study for hepatitis C drug after mid-stage results

BioPharma Dive

2 months ago

Atea plans Phase 3 study for hepatitis C drug after mid-stage results

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

GlobeNewswire

2 months ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Promising US Penny Stocks To Watch In November 2024

Simply Wall St.

2 months ago

Promising US Penny Stocks To Watch In November 2024

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Zacks

2 months ago

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

GlobeNewswire

2 months ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

GuruFocus.com

2 months ago

Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

2 months ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

GlobeNewswire

3 months ago

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

GlobeNewswire

3 months ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight

Simply Wall St.

3 months ago

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Zacks

3 months ago

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

GuruFocus.com

3 months ago

Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ...

Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

4 months ago

Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Zacks

4 months ago

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus

Benzinga

4 months ago

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus

MT Newswires

4 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

MT Newswires

4 months ago

Atea Pharmaceuticals' Phase 3 Study Assessing Bemnifosbuvir for COVID-19 Treatment Fails to Meet Primary Endpoint

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

GlobeNewswire

4 months ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Zacks

5 months ago

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway

GlobeNewswire

5 months ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway

All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy

Zacks

5 months ago

All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Zacks

5 months ago

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

GlobeNewswire

6 months ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

GlobeNewswire

8 months ago

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

GlobeNewswire

8 months ago

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

GlobeNewswire

8 months ago

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

GuruFocus.com

8 months ago

Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

GlobeNewswire

9 months ago

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

GlobeNewswire

9 months ago

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

GlobeNewswire

10 months ago

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript

GuruFocus.com

a year ago

Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

GlobeNewswire

a year ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Investors in York Water (NASDAQ:YORW) have unfortunately lost 15% over the last three years

Simply Wall St.

a year ago

Investors in York Water (NASDAQ:YORW) have unfortunately lost 15% over the last three years

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

GlobeNewswire

a year ago

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

Q3 Earnings Outperformers: Zeta (NYSE:ZETA) And The Rest Of The Advertising Software Stocks

StockStory

a year ago

Q3 Earnings Outperformers: Zeta (NYSE:ZETA) And The Rest Of The Advertising Software Stocks

Advertising Software Stocks Q3 Earnings: AppLovin (NASDAQ:APP) Best of the Bunch

StockStory

a year ago

Advertising Software Stocks Q3 Earnings: AppLovin (NASDAQ:APP) Best of the Bunch

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

Zacks

a year ago

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

GlobeNewswire

a year ago

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Business Wire

a year ago

DTS AutoStage™ Expands into More Vehicle Models Following Video Launch, Developing New Functionality

Business Wire

a year ago

Xperi Expands its Global Footprint with its Powered by TiVo Media Platform for Smart TVs and Connected Car

How Diversified Energy blazed a trail for energy companies

Yahoo Finance Video

a year ago

How Diversified Energy blazed a trail for energy companies

Is It Time To Consider Buying LSB Industries, Inc. (NYSE:LXU)?

Simply Wall St.

a year ago

Is It Time To Consider Buying LSB Industries, Inc. (NYSE:LXU)?

Why Renewable Energy Stocks Plunged on Wednesday

Motley Fool

a year ago

Why Renewable Energy Stocks Plunged on Wednesday

TEGNA and NBC Renew Affiliation Agreement

Business Wire

a year ago

TEGNA and NBC Renew Affiliation Agreement

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock

GlobeNewswire

a year ago

Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock

Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

GlobeNewswire

a year ago

Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

Safe Bulkers, Inc.'s (NYSE:SB) top owners are individual investors with 37% stake, while 26% is held by insiders

Simply Wall St.

a year ago

Safe Bulkers, Inc.'s (NYSE:SB) top owners are individual investors with 37% stake, while 26% is held by insiders

The Zacks Analyst Blog Highlights Assurant, Kinsale Capital Group and NMI Holdings

Zacks

a year ago

The Zacks Analyst Blog Highlights Assurant, Kinsale Capital Group and NMI Holdings

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

PR Newswire

a year ago

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

Will Garmin Ltd. (GRMN) Face Stiffer Competition?

Insider Monkey

a year ago

Will Garmin Ltd. (GRMN) Face Stiffer Competition?

Modernize Unveils In-Depth Homeowner Insights Report: A Guide to Future-Proofing Your Business

Business Wire

a year ago

Modernize Unveils In-Depth Homeowner Insights Report: A Guide to Future-Proofing Your Business

Investing.com

a year ago

Macy's shares jump 20% on $5.8 billion buyout offer: 4 big deal reports

Duff & Phelps Utility and Infrastructure Fund Inc. Announces Dividend and Discloses Sources of Distribution Section 19(a) Notice

Business Wire

a year ago

Duff & Phelps Utility and Infrastructure Fund Inc. Announces Dividend and Discloses Sources of Distribution Section 19(a) Notice

There's A Lot To Like About Ituran Location and Control's (NASDAQ:ITRN) Upcoming US$0.24 Dividend

Simply Wall St.

a year ago

There's A Lot To Like About Ituran Location and Control's (NASDAQ:ITRN) Upcoming US$0.24 Dividend

Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know

Zacks

a year ago

Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know

Why Eagle Bulk Shipping Stock Just Popped 12%

Motley Fool

a year ago

Why Eagle Bulk Shipping Stock Just Popped 12%

Liquidity Services, Inc. (NASDAQ:LQDT) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Liquidity Services, Inc. (NASDAQ:LQDT) Q4 2023 Earnings Call Transcript

SilverBow Resources Announces Closing of Chesapeake Acquisition and Provides Updated 2023 Guidance & Preliminary 2024 Outlook

Business Wire

a year ago

SilverBow Resources Announces Closing of Chesapeake Acquisition and Provides Updated 2023 Guidance & Preliminary 2024 Outlook

5 Things to Know Before Markets Open

Investopedia

a year ago

5 Things to Know Before Markets Open

Do Options Traders Know Something About TETRA Technologies (TTI) Stock We Don't?

Zacks

a year ago

Do Options Traders Know Something About TETRA Technologies (TTI) Stock We Don't?

77 Percent of Consumers Plan to Participate in the 2023 Holiday Shopping Season

PR Newswire

a year ago

77 Percent of Consumers Plan to Participate in the 2023 Holiday Shopping Season

Insider Sell Alert: Director Mark Folse Sells 25,000 Shares of Business First Bancshares Inc (BFST)

GuruFocus.com

a year ago

Insider Sell Alert: Director Mark Folse Sells 25,000 Shares of Business First Bancshares Inc (BFST)

Thomson Reuters StreetEvents

a year ago

Q4 2023 Oaktree Specialty Lending Corp Earnings Call

MicroVision Directors and Executive Team to Purchase Shares

ACCESSWIRE

a year ago

MicroVision Directors and Executive Team to Purchase Shares

HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade

Zacks

a year ago

HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade

Oaktree Specialty Lending (OCSL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a year ago

Oaktree Specialty Lending (OCSL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

GlobeNewswire

a year ago

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Thomson Reuters StreetEvents

a year ago

Q3 2023 BlackRock Capital Investment Corp Earnings Call

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q3 2023 Atea Pharmaceuticals Inc Earnings Call

Mativ Holdings Inc (MATV) Faces Headwinds in Q3 2023 Amid Goodwill Impairment Charge

GuruFocus.com

a year ago

Mativ Holdings Inc (MATV) Faces Headwinds in Q3 2023 Amid Goodwill Impairment Charge

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire

a year ago

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

a year ago

AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why

AN2 Therapeutics to Present at Upcoming Investor Conferences

Business Wire

a year ago

AN2 Therapeutics to Present at Upcoming Investor Conferences

Share on Social Networks: